Physician profile
Joseph A Picca
NPI 1245378215
$326.06
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $63.03 · 2021: $38.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $67.24 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $57.63 | 2019-2021 | |
| Novo Nordisk INC | $36.95 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $25.49 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.99 | 2019 | |
| Valeritas, INC. | $21.37 | 2019 | |
| Therapeuticsmd, INC. | $18.76 | 2019 | |
| Insulet Corporation | $17.99 | 2019 | |
| Pfizer INC. | $15.07 | 2019 | |
| Antares Pharma, INC. | $14.74 | 2019 | |
| Amarin Pharma, INC. | $14.21 | 2019 | |
| Lilly USA, LLC | $12.62 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Picca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.